tiprankstipranks

Zai Lab Limited Reports Strong Revenue Growth and Reduced Losses in 2024

Story Highlights
Zai Lab Limited Reports Strong Revenue Growth and Reduced Losses in 2024

Zai Lab Ltd ( (HK:9688) ) has shared an update.

Zai Lab Limited reported a 49% increase in net product revenue for 2024, reaching $397.6 million, driven by the successful launch and sales of VYVGART, as well as increased sales of ZEJULA and NUZYRA. The company also saw a 23% reduction in net loss to $257.1 million, attributed to revenue growth outpacing operating expenses, despite challenges such as decreased interest income and increased foreign currency loss.

More about Zai Lab Ltd

Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company is primarily engaged in the healthcare industry, with a market focus on oncology, autoimmune, and infectious diseases.

YTD Price Performance: 31.15%

Average Trading Volume: 400

Technical Sentiment Signal: Sell

Current Market Cap: €3.55B

Learn more about 9688 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App